Almeida Cátia, Barata Pedro, Fernandes Ruben
LABMI-PORTIC, Laboratory of Medical & Industrial Biotechnology, Porto Research, Technology and Innovation Center, Porto Polytechnic.
i3S-Instituto de Investigação e Inovação da Universidade do Porto, Porto, Portugal.
Porto Biomed J. 2021 Jan 18;6(1):e106. doi: 10.1097/j.pbj.0000000000000106. eCollection 2021 Jan-Feb.
Lately, the gut microbiota has emerged as an important mediator of the development and the outcomes of certain diseases. It's well known that the gut microbiota plays an important role in maintaining human health. Still far from being completely understood and analyzed is the complexity of this ecosystem, although a close relationship between the gut microbiota and cardiovascular diseases (CVD) has been established. A loss of diversity in the microbiota will lead to physiological changes, which can improve inflammatory or infection states like atherosclerosis and hypertension, the basic pathological process of CVD. Targeting the gut microbiota and its metabolites are new and promising strategies for the treatment and prognosis of CVD.
最近，肠道微生物群已成为某些疾病发生发展及预后的重要调节因子。众所周知，肠道微生物群在维持人类健康方面发挥着重要作用。尽管肠道微生物群与心血管疾病（CVD）之间的密切关系已被确立，但这个生态系统的复杂性仍远未得到完全理解和分析。微生物群多样性的丧失会导致生理变化，进而可能改善诸如动脉粥样硬化和高血压等炎症或感染状态，而这些正是CVD的基本病理过程。针对肠道微生物群及其代谢产物是治疗CVD和预测其预后的新的且有前景的策略。
